Skip to main content

Table 3 Mean changes in PETiT total and domain scores by prior medication in patients switched to long-term lurasidone therapy

From: Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

 

Quetiapine

Olanzapine

Risperidone

Aripiprazole

Ziprasidone

Core Study BL

Extension Study BL

Extension Study EP

Core Study BL

Extension Study BL

Extension Study EP

Core Study BL

Extension Study BL

Extension Study EP

Core Study BL

Extension Study BL

Extension Study EP

Core Study BL

Extension Study BL

Extension Study EP

PETiT Total Score

N

33a

32b

23c

12a

12b

8c

25a

25b

13c

28a

28b

22c

19a

19b

13c

Mean Score (SD)

30.1 (8.0)

35.8 (9.6)

34.0 (6.6)

40.3 (11.8)

43.1 (11.1)

41.4 (12.1)

36.4 (9.9)

40.9 (8.5)

39.4 (11.9)

35.5 (7.6)

40.1 (8.1)

41 (7.7)

35.5 (8.2)

40.9 (7.4)

39.5 (8.6)

Change from Core BL (SD)

--

5.3 (9.1)

3.0 (6.0)

--

1.6 (5.6)

3.1 (7.6)

--

5 (7.5)

8.4 (9.6)

--

4.4 (6.9)

5.5 (6.1)

--

5.4 (7.4)

5.3 (7.2)

p-value

--

0.004

0.026

--

0.082

NEd

--

0.024

0.126

--

0.021

0.002

--

0.005

0.233

Adherence-related Attitude Domain Score

Mean Score (SD)

8.0 (2.2)

9.2 (2.3)

8.7 (2.0)

9.2 (2.4)

10.2 (1.7)

9.4 (1.7)

8.8 (2.1)

10.1 (1.7)

10.1 (2.2)

8.3 (2.1)

10.1 (1.7)

10.2 (1.4)

8.6 (2.0)

9.9 (1.9)

9.8 (1.9)

Change from Core BL (SD)

--

1.3 (2.7)

0.9 (2.5)

--

0.9 (2.1)

0.6 (1.8)

--

1.3 (2.0)

1.8 (2.5)

--

1.7 (2.1)

1.8 (2.5)

--

1.3 (1.9)

1.2 (2.5)

p-value

--

0.004

0.039

--

0.226

NEd

--

0.002

0.138

--

0.001

<0.001

--

0.059

0.119

Psychosocial Functioning Domain Score

Mean Score (SD)

22.1 (7.0)

26.6 (8.5)

25.3 (6.1)

31.1 (10)

32.8 (9.6)

32 (10.5)

27.6 (8.7)

30.8 (7.6)

29.4 (10.3)

27.3 (6.6)

30.0 (7.3)

30.8 (7.3)

26.9 (7.2)

31.1 (6.4)

29.7 (7.6)

Change from Core BL (SD)

--

3.9 (7.5)

2.1 (4.4)

--

0.7 (4.3)

2.5 (6.9)

--

3.8 (6.6)

6.5 (8.0)

--

2.7 (5.8)

3.7 (5.4)

--

4.1 (6.2)

4.2 (5.3)

p-value

--

0.011

0.083

--

0.200

NEd

--

0.058

0.131

--

0.081

0.013

--

0.003

0.228

  1. Abbreviations: BL baseline, EP endpoint, NE Not estimable, PETiT Personal Evaluation of Transitions in Treatment, SD standard deviation
  2. Note: Extension study BL = 6-week follow-up; extension study BL = 30-week follow-up
  3. aNumber of patients with PETiT total and domain scores at core study baseline
  4. bNumber of patients with PETiT total and domain scores at both core study baseline and extension study baseline
  5. cNumber of patients with PETiT total and domain scores at both core study baseline and extension study endpoint
  6. dAlgorithm from regression did not converge due to small population size; p-value is therefore not estimable